Skip to main content

Select Drug Profiles

Specialty Drugs Top the Trends in the 2014 Pipeline

Dalia Buffery, MA, ABD

Abraxane (nab-Paclitaxel) Receives a New Indication for the Treatment of Patients with Metastatic Pancreatic Cancer

Lisa A. Raedler, PhD, RPh

Adempas (Riociguat): A Novel, First-in-Class Therapy Approved for the Treatment of 2 Types of Pulmonary Hypertension

Lisa A. Raedler, PhD, RPh

Amitiza (Lubiprostone): The First Oral Treatment Approved by the FDA for Opioid-Induced Constipation

Anoro Ellipta (Umeclidinium/Vilanterol): First Dual Long-Acting Inhaler for Long-Term Maintenance Treatment of COPD

Lisa A. Raedler, PhD, RPh

Botox (OnabotulinumtoxinA) Now FDA Approved for Overactive Bladder

Breo Ellipta (Fluticasone Furoate/Vilanterol): Fixed-Dose Combination Oral Inhaler Receives FDA Approval for Long-Term Maintenance Treatment of COPD

Brintellix Tablets (Vortioxetine) Approved by the FDA for the Treatment of Major Depressive Disorder

Gazyva (Obinutuzumab) for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology

Lisa A. Raedler, PhD, RPh

Fetzima Extended-Release (Levomilnacipran) Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults

Page 152 of 244
Results 1511 - 1520 of 2434